The antiviral and virucidal compound, hypericin, was studied regarding its activity and possible mechanism against herpes simplex vi#us (HSV-1). It was determined that hypericin ca~ltta slight inhibition of viral adsorption to and penetration of Vero cells. Additionally, yield reduction assays suggested that hypericin was most effective against HSV-1 as a virucidal agent rather than as an intracellular antiviral agent. Fluorescence microscopy revealed that hypericin initially associated with cytoplasmic membranes and that over the course of time it became concentrated in intracellular membranous regions, probably the Golgi apparatus or endoplasmic reticulum (ER). These concentration events failed to inhibit glycosylation of either viral or cellular proteins and were effectively blocked by compounds which inhibit endocytosis or membrane cycling between the ER and Golgi. Based on fluorescence studies, it was determined that hypericin had non-specific affinity for protein and higher affinity for detergent and lipid. The evidence suggested that strong, non-specific association with membranes, both viral and cellular, are probably the basis of hypericin's virucidal and antiviral activity.
Introduction
Several reports describe the antiviral and virucidal activity of hypericin, a compound first isolated by Brockmann et al. (1951) from plants of the genus Hypericum, most notably St. John's wort (Hypericum perforatum) . Meruelo et al.(1988) and Lavie et al. (1989) indicated that hypericin is active in vivo against murine retroviruses such as Friend leukaemia virus and radiation-leukaemia virus (RadLV), while Tang et al. (1990) reported that hypericin is active in vitro against Moloney murine-leukaemia virus. Other reports (Lavie et al., 1989 , Schinazi et al., 1990 have shown activity in vitro against human immunodeficiency virus type 1 (HIV-1). Tang et al. (1990) demonstrated that generally, hypericin inactivates enveloped viruses only. Additionally, they showed that hypericin has little effect against herpes simplex virus type 1 (HSV-1) strain Mayo 1814 when infected cells are incubated in the presence of hypericin. However, Andersen et al. (1991) demonstrated that the yield of infectious HSV-1 strain KOS could be redueed by 1.2 log10 when infected Vero cells are incubated with hypericin at 500 ng ml' (1IJ.M). It was conceded that this may be due to direct inactivation of infectious virions as they were released from infected cells and into the hypericincontaining medium. Hypericin also has been shown by Barnard et al. (1992) to have in vitro activity against a ganciclovir-resistant strain of human cytomegalovirus.
Others have demonstrated the significant role of light in hypericin's virucidal activity. Lopez-Bazzocchi et al. (1991) determined that light potentiates hypericin's in vitro virucidal activities against Sindbis virus and murine cytomegalovirus. The in vitro virucidal activity of hypericin against equine infectious anaemia virus (Kraus et aI., 1990) also was SUbsequently shown to be enhanced by light (Carpenter and Kraus, 1991) .
Although hypericin is being used currently in clinical trials for AIDS, the mechanism by which it exerts its antiviral and virucidal effects is not well understood. Meruelo et al. (1988) concluded that when hypericin is added to cells it associates with the cell membrane within 30 min and postulated that hypericin acts by inhibiting retrovirus assembly at the cell membrane. Lavie et al. (1989) hypothesized that hypericin inhibits retroviral infection by interfering with processing of gag-encoded precursor polyproteins and by directly inactivating mature, properly assembled virions. They demonstrated also that hypericin inhibits RadLV virion reverse transcriptase activity but were unable to see this inhibition against purified reverse transcriptase. However, Schinazi et al. (1990) showed that reverse transcriptase inhibition by hypericin can be reversed effectively by addition of bovine serum albumin (BSA). More recently, Meruelo et a/. (1991) have proposed that hypericin binds to and stabilizes the capsid of HIV-1 thereby protecting it from disruption by SDS detergent. have determined that hypericin neither inhibits binding of HIV-1 gp120 to the CD4 receptor nor membrane fusion events. Valentine (1991) has shown that hypericin can inhibit HIV-1 in vitro under several conditions, including: pre-treatment of either virions or cells, exposure of preinfected cells to hypericin, and addition of non-treated virions and hypericin to cells at the same time.
This study reports on the uptake of hypericin and its subsequent accumulation within cells as well as the in vitro inhibition of HSV-1 (KOS) by hypericin. The fluorescence properties of hypericin allowed the authors to follow the uptake of the compound into various mammalian cells over time. As earlier reports from the laboratory (Andersen et a/., 1991) and from others (Meruelo et et., 1988 , Schinazi et et., 1990 have implicated an affinity of hypericin to associate with detergent, membranes, and proteins, this phenomenon was investigated using fluorescence techniques. Results of these studies indicated that hypericin was localized into membranous regions of cells, that it had a high affinity for lipid, a variable affinity for protein, and that it had a slight inhibitory effect on HSV-1 (KOS) adsorption and penetration.
Results

Cytotoxicity
The cytotoxicity of hypericin was determined in three cell lines: HeLa (human epithelioid cervical carcinoma), Vero (African green monkey kidney), and Hep 38 (human hepatocellular carcinoma). Hypericin at concentrations of 10-50 J..lg mr' was more toxic to non-confluent, rapidly growing cells than to confluent monolayers for each cell line tested. However, hypericin was not toxic for any cells, either confluent or nonconfluent, at concentrations used for antiviral studies (0.1-5 J..lg mr'),
Inhibition of HSV-1 adsorption and penetration
The capacity of hypericin to inhibit viral adsorption and penetration was determined using HSV-1 and Vero cells. Adsorption was inhibited most strongly when both the cells and the virus were pre-treated with hypericin (Table  1) . At each concentration used, pre-treatment of cells alone resulted in only marginal inhibition of adsorption (less than 12%), while pre-treatment of virus alone resulted in better inhibition (about 22%). However, these differences were statistically significant at the 95% confidence level. The effect of treating both cells and virus appeared to be additive with virus pre-treatment contributing most to adsorption inhibition and there was no statistical significant difference between the virus pretreatment group and the combined cell and virus pretreatment group.
Penetration of Vero cells by HSV-1 was affected by pre-treatment of the cells as shown in Table 2 . At 2.0 J..lg mr' (4 J..lM), hypericin was more effective with increasing time (47% inhibition by 90 min). While statistically treatment with 2.0 J..lg mr' of hypericin was significantly better than treatment with either 1.0-0.5 J..lg rnr" , inhibition of penetration was not statistically significant as a function of time from 30 to 90 min.
Yield reduction
The ability of hypericin to inhibit replication of HSV-1 in Vero cells was determined under conditions in which either hypericin was removed from the cells prior to viral infection or it was removed from infected cells prior to the time necessary for one complete viral replication cycle. Data in Table3 indicated that hypericin was only marginally effective against HSV-1 replication when cells Were pre-treated with hypericin and it was removed prior to viral infection. However, when hypericin was left on the cells during most of the viral replication cycle, the compound waS much more effective with 5.0 J..lg mr' resulting in an infectious virus yield of approximately 4% that of the control. Additional data indicated that if hypericin was removed from the cells prior to viral infection, a higher multiplicity of infection (MOl) of 1.0 resulted in a slightly better reduction of virus yield as compared to assays with lower MOls. For example, when Vero cells were treated with hypericin at 5 J.lg mr', the hypericin removed, and the cells infected at an MOl of 1.0, the resulting yield of infectious HSV-1 was decreased to about 72% of control (compare Table 3 ).
Fluorescence microscopy
Results shown in Fig. 1 indicated that initially hypericin associated with the cytoplasmic membranes of Vero cells. By 1 h post-treatment, cytoplasmic membranes fluoresced brightly and hypericin began concentrating into sites within the cells (Fig. 1a ). After 2 h incubation, hypericin still was found to be associated with cytoplasmic membranes, but it was most concentrated in clusters surrounding the cell nuclei, possibly the Golgi apparatus or endoplasmic reticulum (ER) ( Fig. 1b ). By 4 h post-treatment, the perinuclear localization was most pronounced although fluorescence could be seen still at the cytoplasmic membranes (Fig. 1c ). This localization effect appeared somewhat diminished by 6 h, with hypericin still concentrated near the nuclei, but more dispersed throughout the cells (Fig. 1d ). When Vero cells were treated with Brefeldin A at 1J.lg mr" to inhibit membrane cycling between the ER and the cis-and medial-Golgi apparatus (Misumi et al., 1986; Lippincott-Schwartz et al., 1989) , little, if any, concentration of hypericin within the cells took place (Fig. 2 ), but the cytoplasmic membranes still fluoresced substantially. When treated with ammonium chloride (NH 4CI) to inhibit endocytosis (Kim and Groman. 1965. Sandvig and Olsnes, 1980) , Vero cells still took up and concentrated hypericin, but the hypericin appeared to be segregated into larger, spherical bodies and the sites of concentration were predominantly confined to the peripheral edges of the cells rather than adjacent to the nuclei (Fig. 3) .
Results with HeLa cells essentially were the same as those for Vero cells. Additional evidence obtained by using confocal laser microscopy indicated that after 6 h incubation of cells with hypericin, the compound could be found associated with cell nuclear membranes. Although localization of hypericin, possibly to the Golgi or ER, was observed microscopically, experiments revealed no inhibitory effect of the compound on glycosylation of either cellular or viral proteins.
Fluorescence studies and HPLC analysis
Hypericin had an overall affinity for protein, detergent, and lipid based upon relative fluorescence data ( Fig. 4 ). Hypericin had the greatest affinity for L-a-Iyso-phosphatidylcholine (lysolecithin), followed by SOS and, to varying degrees, human serum albumin (HSA), BSA, catalase, and ribonuclease B. However, results indicated that hypericin had little affinity for trypsin.
HSA and catalase were incubated with hypericin and the protein subsequently removed from solution by trichloroacetic acid (TCA) precipitation. HPLC analysis (not shown) of the supernatant fractions showed that HSA removed more hypericin from solution and at a faster rate than catalase. Together with results shown in Fig. 4 , these results indicated that HSA bound most of the free hypericin and reached saturation at low protein concentrations. However, the response for catalase was linear, indicating lack of saturation. 
Discussion
Our results indicated that hypericin had some effect on adsorption of HSV-1 to cells, particularly when the virions were pre-treated with hypericin, and some effect on viral penetration, primarily when the cells were first incubated with the hypericin. However, only a portion of the virucidal activity of hypericin against HSV-1 could be accounted for by inhibition of adsorption or penetration, since treatment of virions with hypericin at 500 ng rnr" resulted in a loss of infectivity of nearly 2 log10 (99%) (Andersen et al., 1991) , while that same concentration reduced viral adsorption by only about 13% (Table 1) . When this concentration of hypericin was used to treat non-infected cells, about 10% inhibition of subsequent viral penetration was noted ( Table 2) . The decrease with time in the effectiveness of hypericin, at 1.0 and 0.5/1g rnl", in" inhibiting viral penetration (Table 2) was probably due to translocation of hypericin into the cells and away from the cytoplasmic membranes. At the highest concentration tested (2.0 /1g rnr '), sufficient hypericin was probably retained in the cytoplasmic membrane to inhibit some viral penetration.
The HSV-1 yield reduction of 1.2 log10 reported by Andersen et al. (1991) was probably due to inactivation of virions as they were released into the surrounding, hypericin-containing medium. In that experiment, cells infected with HSV-1 were incubated for 24h in the presence of hypericin at 500 ng mr'. That incubation time was sufficient to allow at least one complete ' §jral replication cycle. Our results indicated that when h'liericin was removed prior to one viral replication cycle, 5.0/1g mr' resulted in a 96% reduction of infectious virus while 1.0 /1g ml-1 resulted in a 16% reduction. These data indicated intracellular antiviral activity, but the magnitude did not approach the previously reported 1.2 log10 reduction (>90%) obtained at a much lower hypericin concentration. This suggests that hypericin is more effective against HSV-1 in a virucidal role rather than as an intracellular antiviral agent.
Examination of hypericin-treated cells by fluorescence microscopy revealed strong patterns of intense membrane association. As this association was observed over time, it led ultimately to the interaction of hypericin with nuclear membranes. The fact that this pattern of cellular uptake of hypericin could be inhibited by NH 4CI, which is known to perturb endocytic events, and by Brefeldin A, which is known to inhibit membrane cycling from the ER to the Golgi, indicated that uptake and localization of the compound probably depend upon membrane associated intracellular translocation rather than a general diffusion mechanism. Hypericin also may have been localized to the smooth ER. This may permit detoxification of hypericin through ER-associated mechanisms involving mixed-function oxidase complexes (Clark and Waterman, 1991, Khangarot, 1992) . While hypericin's affinity for membrane structures seemed to be non-specific, other fluorescent compounds such as BODIPY ceramide and NBD hexanoic ceramide are known to stain the Golgi apparatus selectively (Lipsky and Pagano, 1985, Pagano et al., 1991) . Schinazi et al. (1990) first demonstrated hypericin's general affinity for protein by showing that addition of BSA blocked hypericin's inhibition of RT activity. However, in Antiviral activity of hypericin against HSV-1 87 that study BSA was the only inhibitory protein used. The results of our protein-hypericin binding studies by fluorescence indicated also that hypericin has not only a general affinity for protein, and that this affinity varies with the particular protein. Takahashi et al. (1989) used hypericin to inhibit protein kinase C in an in vitro assay and concluded that this inhibition, which they deemed to be specific, was the basis of hypericin's antiretroviral activity. However, the amount of hypericin used to inhibit protein kinase C activity (IC 50 of 1.7/1grnr') was far greater than those concentrations used in this study and others to achieve antiviral and virucidal activity. Indeed, the general capacity of hypericin to bind to protein could readily account for the observed inhibition of protein kinase C as well as RT and other proteins.
While hypericin obviously has an affinity for protein, our results indicated also that it has a strong affinity for the detergent, SDS, and an even more pronounced affinity for the lipid, L-a-Iysophosphatidylcholine. A previous report from our laboratory (Andersen et al.,1991) demonstrated the necessity of the non-ionic detergent, Tween-80, to effectively solubilize hypericin. Based upon these results, we conclude that the hypericin-mediated protection of retroviral particles from lysis by non-ionic detergent with the concomitant reduction of RT activity as described by Meruelo et al. (1991) may have been less a function of hypericin binding to and stabilizing the viral capsid than of hypericin's direct association with the detergent. The high affinity of hypericin for lipid is supported also by our microscopic observations which show a strong association with membrane structures. Lavie et al. (1989) have shown previously that hypericin does not inhibit viral protein synthesis. The results of our protein glycosylation experiments support these findings. Meruelo et al. (1988) also have shown that hypericin does not inhibit transport of viral proteins to the cell surface in RadLV infected cells. Additional evidence indicated that hypericin has no inhibitory effect on the secretion of hepatitis B surface antigen from Hep 3B cells which further supports the conclusion that protein transport to cytoplasmic membranes is uninhibited. Meruelo et al. (1991) have shown that hypericin's activity is sensitive to compounds which quench singlet oxygen. Taken with the fact that hypericin's antiviral activity is enhanced by light (Lopez-Bazzocchi et al., 1991, Carpenter and Kraus, 1991) this observation indicates that hypericin is probably most effective as a virucide in vitro when it generates singlet oxygen. During microscopic observations, cells containing hypericin were relatively unstable, being more susceptible to lysis when exposed to light, especially in the UV range. This indicates instability of the cytoplasmic membranes when associated with hypericin. Thomas et al. (1992) have shown that through a process of singlet oxygen generation, photoactivation of hypericin inhibits succinoxidase activity of mitochondria isolated from bovine heart. The high affinity of hypericin for membranous cellular organelles suggests that hypericin may act also at the mitochondrial level in whole cells.
The generation of singlet oxygen by hypericin probably promotes oxidation of unsaturated fatty acids. These Type II photosensitizations are known to oxidize lipids which in turn cause membrane perturbation (Straight and Spikes, 1985) . This oxidation of lipids followed by subsequent destruction of cell membranes would be consistent with the cellular instability observed in our microscopic studies.
Although Degar et al. (1991) have shown that hypericin does not inhibit HIY-1 adsorption or fusion events, the results of this study show that there is some inhibition of these functions for HSY-1. Given hypericin's affinity for lipid, it is likely that it inhibits HSY-1 slightly at each membrane-associated event in the viral replication cycle. The fact that hypericin can be found associated with nuclear membranes of cells incubated with the compound indicates that HSY-1 virions could acquire hypericin as part of their envelope during the budding process and that this might account for results noted in yield reduction assays.
Although it has not been determined yet whether hypericin is subsequently metabolized or secreted after its initial uptake and concentraion in cells, it is apparent that it is taken up by cells in a membrane dependent process as opposed to simple diffusion. It has been demonstrated that it displays differential cytotoxicity depending upon the cell line, and that it inhibits HSY-1 adsorption and penetration events. In addition hypericin's has a variable affinity for protein and a high affinity for lipid have been shown. The data reported here suggest that inhibition of non-specific membrane associated viral replication steps is responsible in large part for the observed antiviral activity of hypericin.
Materials and Experimental procedures
Cells and virus
Vero cells (CCl 81, American Type Culture Collection, Rockville, MD) and Hela cells (Flow labs, Inglewood, CA) were grown in Eagle minimum essential medium (MEM) with non-essential amino acids (Gibco, Grand Island, NY) supplemented with 10% bovine calf serum (BCS) (HyClone, Inc., logan, UT), 20mM HEPES buffer (pH7.35) and 50!lgml-1 gentamicin reagent solution. Hep 3B cells (HB 8064, American Type Culture Collection), which contain an integrated hepatitis B virus genome and secrete hepatitis B surface antigen, were grown similarly except medium was also supplemented with sodium pyruvate and 10% fetal bovine serum (FBS) (Intergen, Purchase, NY) was substituted for BCS.
HSV-1 (KOS) was propagated in Vero cells as described previously (Kirsi et al., 1984) . HSV-1 for adsorption assays was prepared by infecting Vero cells with virus in Dulbecco's phosphate buffered saline (PBS) at an MOl of 3-5 for an adsorption period of 2 h at 37°C. The inoculum was removed and MEM with 1% FBS was added along with 3H-glucosamine (ICN Biomedicals, Inc., Costa Mesa, CA) at zoucrmr". Infected cells were incubated 48h at 37°C. At that time, they were twice frozen at -70°C and thawed then centrifuged at 500 x g for 10 min at 4°C. The supernatant fluid was removed and centrifuged at 3 x 10 4 9 and 4°C for 45 min in an SS-34 rotor. The supernatant fraction was decanted and the virus pellet washed once in cold PBS. The pellet was then resuspended in cold PBS and sonicated for 10 s to disrupt clumps. This labelled virus pool was subdivided and frozen at -70°C.
Preparation of hypericin
Hypericin was synthesized and purified as previously described (Barnard et al., 1992) . Methanol was removed from the hypericin by drying under a stream of nitrogen. This dried hypericin was then used to make a stock solution at 100!lg rnl" (200!lM) by dissolving it in PBS containing 0.05% Tween-80.
Cytotoxicity
Cells were seeded in 24-well plates (Corning) at either 5 x 10 4 or 2.5 x 10 5 per well in 1 ml medium and incubated overnight at 37°C and 5% CO 2 in a humidified incubator. Hypericin was added to the cells at final concentrations of 50, 10, 5, 1, or 0 !lg rnr? (100, 20, 10, 2, or 0 !lM) and, following an additional 24 h incubation, the cells were washed twice with PBS, trypsinized, collected, and counted using a Coulter counter. Experiments were performed in triplicate using duplicate wells per sample.
Viral adsorption assay
To determine the effect of hypericin on adsorption of HSV-1 to Yero cells, a modification of the procedure described by Herold et al. (1991) was used. Vero cells were seeded at 6 x 10 5 cells per well into 12-well plates (Corning) and incubated at 37°C overnight to confluence. In one set of experiments, confluent Vero cell monolayers were pre-treated with hypericin in serumfree MEM at 5, 2, 1, 0.5, 0.25, 0.1, or O!lg mr' (10,4, 2, 1, 0.5, 0.2, or a!lM) for 1 h at 3?OC. Then the medium with hypericin was removed and PBS with 2% BSA was added to the cell monolayers followed by incubation for 1h at 3?OC in a step designed to block non-specific virus adsorption. At that point, the cells were washed twice with PBS. labelled HSV-1 was then added to the monolayers at 3 p.f.u. per cell and incubated 4 h at 4°C on a rocker platform. The monolayers were rinsed twice with cold PBS and the cells were then lysed in their wells with PBS containing 1% SDS and 1% Triton x-ioo. These samples were transferred to scintillation vials containing BIOFlUOR (New England Nuclear, Boston, MA) and counted by liquid scintillation.
In a second experiment, labelled HSV-1 was pre-treated with hypericin at 5, 2, 1, 0.5, 0.25, 0.1, or Ouq rnr ' by incubating the virus with the compound in PBS for 1h at 37°C. Following incubation, the treated virus was inoculated onto confluent monolayers of Vero cells which had been incubated 1 h with PBS containing 2% BSA. Adsorption was for 4 h at 4°C and the samples were then counted by liquid scintillation as just described.
In a third set of experiments, both virus and cells were pretreated with hypericin at 2, 1, 0.5, 0.25, 0.1, and 0 /1g mr" . Adsorption was determined as described above.
Vifalpeneuailonassay
The ability of HSV-1 to penetrate hypericin-treated Vero cells was determined by modification of the procedure of Highlander et a/. (1987) . Briefly, duplicate wells of confluent Vero cells in 24-well plates (Corning) were treated with hypericin at 2, 1,0.5, or 0 /1g mr' for 1 h at 37"C. The cells were rinsed twice with PBS and 100 p.t.u. of virus was added to each well. Following 2 h of incubation at 4°C, the monolayers were washed twice with PBS, MEM was added, and the cells were incubated at 37°C for 30, 60, or 90 min. At those times, medium was removed, cells were treated with citric acid buffer (40 mM citric acid, 10mM KCI, 135mM NaCI, pH3.0) for 1 min, and the monolayers were rinsed twice with PBS. Overlay medium (MEM with 1% BCS and 1% methylcellulose) was added to each well followed by incubation at 37°C until plaqp'es formed. Then cells were fixed with 10% formalin and stail ,1'd with a 1% crystal violet solution. This experiment was performed twice.
Glycosylation of HSV-1 and Vero cell proteins
Vero cells in confluent monolayers in 24-well plates were pretreated 5 h at 37"C with 5, 1, 0.5, or 0 /1g rnl" hypericin. Hypericin was removed and the cells were either infected with HSV-1 at an MOl of 5 or mock-infected. After 1 h adsorption at 37°C, hypericin was added to the medium and the samples were incubated 4 h at 37°C. 3H-glucosamine was added to give final concentrations of 15-20 /1Ci mr' and the cells were incubated overnight. At 24 h post infection, media was removed, cell layers were washed twice with PBS, and deionized water was added to each sample which was then frozen and thawed twice. Samples were TCA precipitated and filtered through Whatman GF/C filters. The filters were air dried, placed into scintillation vials along with BIOFLUOR, and label incorporation was measured using a Packard 460C liquid scintillation counter. Experiments were done twice using duplicate wells each time.
HSV-1 yield reduction assay
Virus-yield reductions were performed essentially as described previously (Andersen et a/., 1991) except that in one set of experiments, hypericin at 5, 1, 0.1, or 0 /1g rnr' was used to pre-treat confluent monolayers of Vero cells for 6 h in 24-well plates. Medium with hypericin was removed and HSV-1 was added at MOls of 1.0, 0.1, or 0.01. The infected cells were incubated 24 h at 37"C in hypericin-free medium. At that time, they were twice frozen and thawed and the infectious virus was titred by standard plaque assay methods.
In a second yield reduction experiment, hypericin at 5, 2, 1, 0.1, or 0 /1g mr' was used to pre-treat Vero cells for 6 h. The medium with hypericin was removed and the cells were infected with HSV-1 at an MOl of 0.01 for an adsorption period Antiviral activity of hypericin against HSV-1 89 of 1 h at 37°C. Hypericin was then added once again at the same concentrations as those used to pre-treat the cells and the infected cells were incubated an additional 13 hat 37°C. At that time, the hypericin was removed, fresh medium added, and the infected cells were incubated for another 10 h at 37"C. The samples were twice frozen and thawed then titred as described above. All assays were done in triplicate using duplicate wells per sample.
Fluorescence microscopy
Vero and HeLa cells were seeded at approximately 2 x 10 4 cells per chamber into two-chamber slides (Lab-Tek, Nunc, Inc., Naperville, IL) and incubated overnight. Hypericin was added to give a final concentration of 1/1gml-1 (2/1M). Then cells were incubated for 0, 1/2, 1,2,4, 6, or 24 hat 37°C. Followlnq these time periods, the cells were washed twice with PBS and covered with a coverslip. A representative field of view was photographed using a Nikon Labophot microscope equipped with a Nikon super high pressure mercury lamp and a Nikon N2000 camera with Ektachrome 160T film (Kodak, Rochester, NY). The range exposure time was 10-20 s. Experiments with Brefeldin A (Sigma Chemical, St. Louis, MO) were similar except the cells were seeded at 1 x 10 4 per chamber. After overnight incubation, Brefeldin A was added to a final concentration of 1 or 5/1grnr" followed by an additional 18 h incubation. At that time, hypericin was added to a final concentration of 2/1M and the cells were incubated 6 h prior to microscopic examination. In other experiments, NH 4Cl at 10 mM was added 18 h prior to addition of the hypericin in order to inhibit endocytosis. Additionally, Vero cells grown in the presence of 1/1gmr" hypericin for 6 h were observed using a Zeiss laser scanning microscope.
Reletive fluorescence of hypericin and HPLC analysis
Hypericin at 0.5/1gml-1 in PBS was incubated 24h at 37°C in the presence of 400,200, 100,20, 10, or 0 /1g mr" of the following compounds: trypsin, bovine serum albumin (BSA), ribonuclease B, catalase, human serum albumin (HSA), sodium dodecyl sulphate (SOS), or L-a-Iysophosphatidylcholine (lysolecithin). The fluorescence of hypericin with each compound was measured using a fluorescence spectrophotometer (Perkin-Elmer LS-3) with excitation at 551 nm and emission at 599 nm. Relative fluorescence was determined after subtracting individual fluorescence values of hypericin and the compounds. Hypericin was also added to HSA and catalase as described above. Following the 24-h incubation, samples were put on ice and the protein was precipitated by adding enough 100% ice-cold TCA to make the samples 20% in TCA. All samples were kept on ice for 30 min then centrifuged 20 min at 11500 9 at 4°C. The supernatant fractions were collected, prepared for HPLC by passage through SEP-PAK C 1 8 preparatory columns (Waters Associates, Milford, MA), and assayed for hypericin content by reversed-phase HPLC. Each sample was separated isocratically with 72% B (2% acetic acid in acetonitrile) in A (2% acetic acid in water) through a Microsorb 5/1 C 1 8 column (4.6 mm x 25 cm) (RAININ, Emeryville, CAl at a flow rate of 2 ml rnln". Hypericin was detected using an FL 748 fluorometer (McPherson) equipped with a mercury lamp and a 470 nm cutoff filter and at 285 nm in the UV range. The lower detection limit for hypericin was under 200 pg per injection.
Statistical methodology
Data were examined for significance at the 95% confidence level by analysis of variance, with unbalanced data (for Table 1 ), and by the Bonferoni pairwise comparison procedure.
